Search for: "Daubert v. Merrell Dow Pharmaceuticals, Inc."
Results 101 - 120
of 220
Sorted by Relevance
|
Sort by Date
31 Mar 2016, 6:00 am
Merrell Dow Pharmaceuticals, Inc., 509 U. [read post]
21 Oct 2018, 10:29 am
Merrell Dow Pharmaceuticals, Inc., U.S. [read post]
25 Jan 2011, 10:06 am
Merrell Dow Pharmaceuticals, 509 U.S. 579 (1993). [read post]
16 Mar 2023, 4:30 am
Merrell Dow Pharmaceuticals, Inc., (1993), on the standards for expert testimony, with 24 departing states, United States v. [read post]
19 Nov 2023, 2:31 pm
Merrell Dow Pharmaceuticals, Inc.,[2] The Supreme Court suggested that peer review of studies relied upon by a challenged expert witness should be a factor in determining the admissibility of that expert witness’s opinion. [read post]
11 Mar 2011, 2:03 pm
In 1993 in Daubert v. [read post]
29 Jan 2022, 6:24 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993), Fed.Rules, Evid.Rules 104(a), 702. [read post]
5 Apr 2010, 1:01 pm
Dow Merrell Pharmaceuticals, Inc., which prohibit the use of inaccurate, nonspecific tests and/or conclusory reports because they do not prove the presence of marijuana in a seized substance. [read post]
15 May 2014, 9:36 am
Breg Inc., 613 F.3d 1329, 1342 (11th Cir. 2010); see also Norris v. [read post]
17 Jan 2014, 8:27 pm
Merrell Dow Pharmaceuticals, Inc., the United States Supreme Court held for the first time that, to be admissible, scientific evidence must be both scientifically valid and properly applicable to the facts at issue in the case. [read post]
17 Mar 2014, 6:57 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
22 Feb 2011, 7:27 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in analyzing the expert presentations relating to the Rule 23 requirements, Plaintiffs contend that the Ninth Circuit found this to be no abuse of discretion, and that it did not matter because the district court judge was "guided by Daubert," concluded that the expert opinions were "based on valid principles," and were "sufficiently probative" of the Rule 23… [read post]
22 Feb 2011, 7:27 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in analyzing the expert presentations relating to the Rule 23 requirements, Plaintiffs contend that the Ninth Circuit found this to be no abuse of discretion, and that it did not matter because the district court judge was "guided by Daubert," concluded that the expert opinions were "based on valid principles," and were "sufficiently probative" of the Rule 23 requirements. [read post]
27 May 2010, 3:40 pm
”Merrell Dow Pharmaceuticals, Inc. v. [read post]
4 Mar 2012, 9:02 am
Merrill Dow Pharmaceuticals, Inc., 874 F.2d 307, 311-12 (5th Cir. 1989)(“Fortunately, we do not have to resolve any of the above questions [as to bias and confounding], since the studies presented to us incorporate the possibility of these factors by the use of a confidence interval. [read post]
27 Jul 2017, 2:00 am
MERRELL DOW PHARMACEUTICALS, INC 509 U.S. 579 (1993)KOKKONEN V. [read post]
17 Jan 2014, 8:27 pm
Merrell Dow Pharmaceuticals, Inc., the United States Supreme Court held for the first time that, to be admissible, scientific evidence must be both scientifically valid and properly applicable to the facts at issue in the case. [read post]
31 Dec 2009, 2:34 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), and its federal and state progeny. [read post]
28 Jun 2012, 7:10 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
25 Apr 2015, 11:03 am
The first edition of the Reference Manual on Scientific Evidence [Manual] was published in 1994, a year after the Supreme Court delivered its opinion in Daubert. [read post]
